Agonistic Properties of Cannabidiol at 5-HT1a Receptors

被引:0
作者
Ethan B. Russo
Andrea Burnett
Brian Hall
Keith K. Parker
机构
[1] The University of Montana,Skaggs School of Pharmacy
来源
Neurochemical Research | 2005年 / 30卷
关键词
Cannabis; cannabidiol; cAMP; G Proteins; marijuana; serotonin; THC;
D O I
暂无
中图分类号
学科分类号
摘要
Cannabidiol (CBD) is a major, biologically active, but psycho-inactive component of cannabis. In this cell culture-based report, CBD is shown to displace the agonist, [3H]8-OH-DPAT from the cloned human 5-HT1a receptor in a concentration-dependent manner. In contrast, the major psychoactive component of cannabis, tetrahydrocannabinol (THC) does not displace agonist from the receptor in the same micromolar concentration range. In signal transduction studies, CBD acts as an agonist at the human 5-HT1a receptor as demonstrated in two related approaches. First, CBD increases [35S]GTPγS binding in this G protein coupled receptor system, as does the known agonist serotonin. Second, in this GPCR system, that is negatively coupled to cAMP production, both CBD and 5-HT decrease cAMP concentration at similar apparent levels of receptor occupancy, based upon displacement data. Preliminary comparative data is also presented from the cloned rat 5-HT2a receptor suggesting that CBD is active, but less so, relative to the human 5-HT1a receptor, in binding analyses. Overall, these studies demonstrate that CBD is a modest affinity agonist at the human 5-HT1a receptor. Additional work is required to compare CBD’s potential at other serotonin receptors and in other species. Finally, the results indicate that cannabidiol may have interesting and useful potential beyond the realm of cannabinoid receptors.
引用
收藏
页码:1037 / 1043
页数:6
相关论文
共 147 条
[1]  
Russo E. B.(2003)Introduction: Cannabis: from pariah to prescription J. Cann. Therap. 3 1-29
[2]  
Carlini E. A.(1981)Hypnotic and antiepileptic effects of cannabidiol J. Clin. Pharmacol. 21 417S-427S
[3]  
Cunha J. M.(1998)Cannabidiol, (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants Proc. Natl. Acad. Sci. USA. 95 8268-73
[4]  
Hampson A. J.(2004)Neuroprotective effect of cannabidiol, a non-psychoactive component from cannabis sativa, on beta-amyloid-induced toxicity in PC 12 cells J. Neurochem. 89 134-141
[5]  
Grimaldi M.(2004)Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults J. Clin. Psychopharmacol. 24 305-313
[6]  
Axelrod J.(2001)Cannabinoid receptors are absent in insects J. Comp. Neurol. 436 423-9
[7]  
Wink D.(1997)“Pharmacology of cannabinoid CB1 and CB2 Receptors” Pharmacol. Therap. 74 129-180
[8]  
Iuvone T.(1998)“Comparative receptor binding analysis of cannabinoid agonists and antagonists” J. Pharm. Exp. Therap 285 285-292
[9]  
Esposito G.(1998)“Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity at delta 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors” Life Sci. 63 1 PL1-PL6
[10]  
Esposito R.(2001)Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? J. Cannabis Therap. 1 103-132